Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Case-control study on effectiveness of nirsevimab in uninsured-eligible children in Mie Prefecture
jRCT1040250184Recruiting
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Trial of nirsevimab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by none. Primary endpoint: Primary effectiveness of nirsevimab against RSV. Started Feb 2026; status: recruiting.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT1040250184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1040250184.